Compared side by side
Thymosin Alpha-1 vs LL-37: how they differ
The short answer
Both work on the immune system, in different ways: thymosin alpha-1 is a thymic peptide that helps T-cells mature and raises natural killer cell activity, and LL-37 is the body’s own antimicrobial peptide, which in lab studies kills bacteria, fungi and some viruses. Thymosin alpha-1 is a prescription drug (thymalfasin) in about 35 countries, mainly for hepatitis B, though not in the US; injected LL-37 hasn’t been studied in people. Thymosin alpha-1 is taken twice a week, LL-37 daily or every other day in short cycles.
Side by side
| Compared | Thymosin Alpha-1 | LL-37 |
|---|---|---|
| Category | Healing & recovery | Healing & recovery |
| Also known as | Tα1, Thymalfasin, Zadaxin | Cathelicidin, hCAP-18, CAP-18 |
| What it is | A naturally occurring thymic peptide that fine-tunes the immune system: it helps T-cells mature and raises natural killer cell activity. | Your body's own antimicrobial peptide. |
| How it works | Naturally occurring thymic peptide that modulates immune function. It stimulates T-cell maturation and NK cell activity, and has antiviral and anti-tumor effects; the anti-tumor work is mostly in cells and animals, and human results are mixed. | Human antimicrobial peptide with broad-spectrum antimicrobial activity. In lab and animal studies it modulates innate immunity, breaks up biofilms and promotes wound healing; it can be anti- or pro-inflammatory depending on context. |
| Commonly reported | Fewer or shorter colds over a season, with little to feel day to day. It's a prescription drug (thymalfasin) in about 35 countries, mainly for hepatitis B, though not in the US, and trial results are mixed. | Noticeable injection-site redness or itching, and for some a flu-like, achy feeling in the first days. As a drug it has only been tested as a topical treatment for leg and foot ulcers, with mixed results; injected LL-37 hasn't been studied in people. |
| Studied range | Research range: 1–1.6 mg. Studied in research — not a recommendation. | Research range: 100–300 mcg. Studied in research — not a recommendation. |
| How often | 2x/week | Daily or EOD |
| Half-life | ~2 hours (Zadaxin label, after a SubQ dose) | Unknown in humans (short; broken down by proteases) |
| Route | SubQ injection | SubQ injection |
| Typical run | Community cycles typically run 4–6 weeks, 2x/week, or as needed for immune support. The hepatitis B trials ran far longer: 1.6 mg twice a week for 26 or 52 weeks (Chien 1998). | Short cycles of 2–4 weeks due to limited data. Conservative approach advised. |
| Evidence | Established: clinical trials or FDA-approved use exists | Emerging: primarily preclinical / limited human data |
| Common side effects | Injection site reaction, fatigue, mild flu-like symptoms | Injection site pain, redness, mild systemic inflammation |
- Category
- Thymosin Alpha-1Healing & recovery
- LL-37Healing & recovery
- Also known as
- Thymosin Alpha-1Tα1, Thymalfasin, Zadaxin
- LL-37Cathelicidin, hCAP-18, CAP-18
- What it is
- Thymosin Alpha-1A naturally occurring thymic peptide that fine-tunes the immune system: it helps T-cells mature and raises natural killer cell activity.
- LL-37Your body's own antimicrobial peptide.
- How it works
- Thymosin Alpha-1Naturally occurring thymic peptide that modulates immune function. It stimulates T-cell maturation and NK cell activity, and has antiviral and anti-tumor effects; the anti-tumor work is mostly in cells and animals, and human results are mixed.
- LL-37Human antimicrobial peptide with broad-spectrum antimicrobial activity. In lab and animal studies it modulates innate immunity, breaks up biofilms and promotes wound healing; it can be anti- or pro-inflammatory depending on context.
- Commonly reported
- Thymosin Alpha-1Fewer or shorter colds over a season, with little to feel day to day. It's a prescription drug (thymalfasin) in about 35 countries, mainly for hepatitis B, though not in the US, and trial results are mixed.
- LL-37Noticeable injection-site redness or itching, and for some a flu-like, achy feeling in the first days. As a drug it has only been tested as a topical treatment for leg and foot ulcers, with mixed results; injected LL-37 hasn't been studied in people.
- Studied range
- Thymosin Alpha-1Research range: 1–1.6 mg. Studied in research — not a recommendation.
- LL-37Research range: 100–300 mcg. Studied in research — not a recommendation.
- How often
- Thymosin Alpha-12x/week
- LL-37Daily or EOD
- Half-life
- Thymosin Alpha-1~2 hours (Zadaxin label, after a SubQ dose)
- LL-37Unknown in humans (short; broken down by proteases)
- Route
- Thymosin Alpha-1SubQ injection
- LL-37SubQ injection
- Typical run
- Thymosin Alpha-1Community cycles typically run 4–6 weeks, 2x/week, or as needed for immune support. The hepatitis B trials ran far longer: 1.6 mg twice a week for 26 or 52 weeks (Chien 1998).
- LL-37Short cycles of 2–4 weeks due to limited data. Conservative approach advised.
- Evidence
- Thymosin Alpha-1Established: clinical trials or FDA-approved use exists
- LL-37Emerging: primarily preclinical / limited human data
- Common side effects
- Thymosin Alpha-1Injection site reaction, fatigue, mild flu-like symptoms
- LL-37Injection site pain, redness, mild systemic inflammation
Typical run: Community practice — opinions vary. Not a clinical recommendation.

Week by week
Each entry’s cards by day window, as the compound pages show them. Day 1 is the day you start it.
Thymosin Alpha-1
- Day 1–7 Your immune system is getting instructions
- Day 7–14 The immune side is ramping up
- Day 14–28 Where a common cycle ends
LL-37
- Day 1–7 Some feel a flu-like wave early
- Day 7–21 Weeks 1 to 3: check what changed
- Day 21–28 Cycle wrap-up — time to assess
Together or one or the other
Thymosin Alpha-1 and LL-37 are a common stack: each lists the other among its common stacks.
Community · LL-37
An immune-support trio
Three immune layers at once: LL-37 works on microbes directly, KPV calms inflammation, and thymosin alpha-1 tunes the adaptive side. Commonly stacked for immune support; users judge it by how they feel over several weeks.
Questions people ask
How long do Thymosin Alpha-1 and LL-37 last?
The half-life of Thymosin Alpha-1 is ~2 hours (Zadaxin label, after a SubQ dose). The half-life of LL-37 is unknown in humans (short; broken down by proteases).
How often are Thymosin Alpha-1 and LL-37 taken?
Thymosin Alpha-1: 2x/week. Route: SubQ injection. LL-37: daily or EOD. Route: SubQ injection.
How are Thymosin Alpha-1 and LL-37 dosed in research?
The research range for Thymosin Alpha-1 is 1–1.6 mg. The research range for LL-37 is 100–300 mcg. Studied in research — not a recommendation.
What are the common side effects of Thymosin Alpha-1 and LL-37?
For Thymosin Alpha-1, the library lists: injection site reaction, fatigue, mild flu-like symptoms. For LL-37: injection site pain, redness, mild systemic inflammation.
Are Thymosin Alpha-1 and LL-37 taken together?
Thymosin Alpha-1 and LL-37 are a common stack: each lists the other among its common stacks. Three immune layers at once: LL-37 works on microbes directly, KPV calms inflammation, and thymosin alpha-1 tunes the adaptive side. Commonly stacked for immune support; users judge it by how they feel over several weeks.